 The FDA has expanded the Emergency Use Authorization EUA for bamlanivimab 700 mg and etesevimab 1400 mg administered together to include post-exposure prophylaxis in certain individuals to prevent SARS-CoV-2 infection. Bamlanivimab emerged from the collaboration between Eli Lilly And Co NYSE: LLY and AbCellera Biologics Inc NASDAQ: ABCL. 